Carl Domino’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$1.06M Sell
13,124
-695
-5% -$53.1K 1.3% 39
2017
Q2
$978K Sell
13,819
-1,905
-12% -$127K 1.14% 43
2017
Q1
$1.07M Buy
15,724
+2,679
+21% +$188K 1.17% 44
2016
Q4
$934K Sell
13,045
-15,501
-54% -$1.15M 1% 47
2016
Q3
$2.22M Buy
28,546
+10,456
+58% +$849K 2.1% 3
2016
Q2
$1.51M Buy
18,090
+88
+0.5% +$7.81K 1.41% 25
2016
Q1
$1.65M Sell
18,002
-599
-3% -$54K 1.51% 20
2015
Q4
$1.88M Hold
18,601
1.47% 21
2015
Q3
$1.83M Sell
18,601
-2,534
-12% -$281K 1.46% 27
2015
Q2
$2.48M Buy
21,135
+423
+2% +$46.2K 1.69% 12
2015
Q1
$2.03M Buy
20,712
+300
+1% +$30.5K 1.52% 11
2014
Q4
$1.92M Buy
20,412
+331
+2% +$34.2K 1.04% 47
2014
Q3
$2.14M Buy
20,081
+275
+1% +$26.9K 1.15% 44
2014
Q2
$1.64M Buy
19,806
+500
+3% +$38.9K 0.82% 53
2014
Q1
$1.37M Buy
19,306
+270
+1% +$21.2K 0.73% 53
2013
Q4
$1.43M Buy
19,036
+150
+0.8% +$10.4K 0.78% 52
2013
Q3
$1.19M Buy
18,886
+1,080
+6% +$64.5K 0.67% 52
2013
Q2
$913K Buy
+17,806
New +$928K 0.52% 57

Other funds holding GILD

Carl Domino's GILD Position: Q3 2017 in Review

Carl Domino reduced its Gilead Sciences (GILD) stake by 5% in Q3 2017, selling an estimated $53.1K and leaving 13,124 shares worth $1.06M. The position accounts for 1.3% of the portfolio, ranked #39.

Carl Domino first reported a position in GILD in Q2 2013 and has held it in 18 quarters since. The position peaked at $2.48M in Q2 2015. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Carl Domino held 13,124 shares of Gilead Sciences worth $1.06M as of Q3 2017.
  • Carl Domino sold 695 Gilead Sciences shares in Q3 2017, an estimated $53.1K.
  • Gilead Sciences made up 1.3% of Carl Domino's portfolio in Q3 2017, its #39 holding.
  • Carl Domino first reported a position in Gilead Sciences in Q2 2013 and has held it in 18 quarters since.
  • Carl Domino's Gilead Sciences position peaked at $2.48M in Q2 2015.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Carl Domino's 13F filing for Q3 2017, filed 7 Nov 2017.